tll018
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 26, 2020 (NCT04243083)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase TYK2INHIBITOR
TYK2 inhibitor
- Jak1 proteinINHIBITOR
JAK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05772520 | Phase 2 | Jan 19, 2023 | Hangzhou Highlightll Pharmaceutical Co., Ltd |
| NCT05342428 | Phase 1 | Jun 10, 2022 | Hangzhou Highlightll Pharmaceutical Co., Ltd |
| NCT05373355 | Phase 1 | May 10, 2022 | Hangzhou Highlightll Pharmaceutical Co., Ltd |
| NCT05121402 | Phase 2 | Dec 30, 2021 | Hangzhou Highlightll Pharmaceutical Co., Ltd |
| NCT04243083 | Phase 1 | Jan 26, 2020 | Frontage Laboratories, Inc., Hangzhou Highlightll Pharmaceutical Co., Ltd |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hangzhou Highlightll Pharmaceutical Co., Ltd | For profit | 5 | 5 | 2 | 2020 |
| Frontage Laboratories, Inc. | For profit | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1